Search research articles
Contact Us
Filters
Showing results (31-40 of 212) with videos related to
Page
of 22
Sort By:
Current Hematologic Malignancy Reports
|
April 29, 2010
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Rami S Komrokji, Jeffrey E Lancet, Alan F List
Hematology Reports
|
December 21, 2011
Immune dysregulation in myelodysplastic syndrome
Chiharu Sugimori, Alan F List, Pearlie K Epling-Burnette
Therapeutic Advances in Hematology
|
April 5, 2013
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
Vu H Duong, Rami S Komrokji, Alan F List
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2002
Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives
Herson I Quiñones, Alan F List, Eugene W Gerner
Current Hematologic Malignancy Reports
|
March 29, 2011
Management of lower-risk myelodysplastic syndromes: the art and evidence
Rami S Komrokji, Mikkael A Sekeres, Alan F List
Expert Opinion on Pharmacotherapy
|
August 1, 2014
Update on the pharmacotherapy for myelodysplastic syndromes
Vu H Duong, Rami S Komrokji, Alan F List
Cancer Control : Journal of the Moffitt Cancer Center
|
October 9, 2012
Advances in the management of myelofibrosis
Rami S Komrokji, Srdan Verstovsek, Eric Padron, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
January 24, 2007
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes
Alan F List, Amanda F Baker, Sylvan Green, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 3, 2013
Prognostic factors and risk models in myelodysplastic syndromes
Rami S Komrokji, Eric Padron, Jeffrey E Lancet, et al.
Expert Opinion on Emerging Drugs
|
November 21, 2012
Emerging immunosuppressive drugs in myelodysplastic syndromes
Pearlie K Epling-Burnette, Jessica McDaniel, Sheng Wei, et al.
Page
of 22
Search research articles
Search
Showing results (31-40 of 212) with videos related to
Sort By:
Page
of 22
Current Hematologic Malignancy Reports
|
April 29, 2010
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Rami S Komrokji, Jeffrey E Lancet, Alan F List
Hematology Reports
|
December 21, 2011
Immune dysregulation in myelodysplastic syndrome
Chiharu Sugimori, Alan F List, Pearlie K Epling-Burnette
Therapeutic Advances in Hematology
|
April 5, 2013
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
Vu H Duong, Rami S Komrokji, Alan F List
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2002
Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives
Herson I Quiñones, Alan F List, Eugene W Gerner
Current Hematologic Malignancy Reports
|
March 29, 2011
Management of lower-risk myelodysplastic syndromes: the art and evidence
Rami S Komrokji, Mikkael A Sekeres, Alan F List
Expert Opinion on Pharmacotherapy
|
August 1, 2014
Update on the pharmacotherapy for myelodysplastic syndromes
Vu H Duong, Rami S Komrokji, Alan F List
Cancer Control : Journal of the Moffitt Cancer Center
|
October 9, 2012
Advances in the management of myelofibrosis
Rami S Komrokji, Srdan Verstovsek, Eric Padron, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
January 24, 2007
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes
Alan F List, Amanda F Baker, Sylvan Green, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 3, 2013
Prognostic factors and risk models in myelodysplastic syndromes
Rami S Komrokji, Eric Padron, Jeffrey E Lancet, et al.
Expert Opinion on Emerging Drugs
|
November 21, 2012
Emerging immunosuppressive drugs in myelodysplastic syndromes
Pearlie K Epling-Burnette, Jessica McDaniel, Sheng Wei, et al.
Page
of 22